Introduction
Pdcd4 has been described recently as a new tumor suppressor gene, its overexpression being sufficient to inhibit 12-O-Tetradecanoylphorbol 13-acetate 4b,9a, 12b,13a,20-Pentahydroxytiglia-1,6-dien-3-one 12-tetradecanoate 13-acetate (TPA)-induced neoplastic transformation (Cmarik et al., 1999; Yang et al., 2001a) , as well as tumor promotion and progression to carcinomas in a transgenic mouse model (Jansen et al., 2005) . It was identified in the JB6 mouse epidermal clonal genetic variant cell system as a 64 kDa protein, being preferentially expressed in tumor-promoter-resistant cells and suppressed in promotion-sensitive cells undergoing neoplastic transformation (Cmarik et al., 1999) . The pdcd4 cDNA is identical to murine MA-3 and TIS genes (Shibahara et al., 1995; Onishi and Kizaki, 1996) , and there is a high homology to the human genes H731 and 197/15 (Azzoni et al., 1998; Yoshinaga et al., 1999) . The human gene is located at chromosome 10q24 (Soejima et al., 1999) and its expression has been reported, for example, in human interleukin 12 (IL-12)-induced natural killer (NK) and T cells (Azzoni et al., 1998) , small duct epithelial cells of the normal mammary gland (Soejima et al., 1999; Yoshinaga et al., 1999) , a growth-suppressed human neuroendocrine pancreatic carcinoma cells (Stalberg et al., 2001) , normal human lung tissue (Chen et al., 2003) , or senescent human fibroblasts (Kang et al., 2002) . Pdcd4 has been suggested to be linked to the process of apoptosis in response to different inducers (Shibahara et al., 1995; Zhang and DuBois, 2001) , and has been shown to be regulated by topoisomerase inhibitors (Onishi et al., 1998) , COX-2 inhibitors (Zhang and DuBois, 2001) , Myb (Schlichter et al., 2001) and Akt (Palamarchuk et al., 2005) . Molecules regulated by Pdcd4 include p21 (Go¨ke et al., 2004) , Cdk4, ornithine decarboxylase (Jansen et al., 2005) , carbonic anhydrase II (LankatButtgereit et al., 2004) and JNK/c-Jun/AP-1 (Bitomsky et al., 2004; Yang et al., 2006) . Pdcd4 interacts with the translation initiation factors eIF4A and eIF4G and inhibits translation (Yang et al., 2004; Zakowicz et al., 2005) . However, little is known of specific gene promoters and cognate transcription factors that mediate Pdcd4-regulated gene expression. In addition, although Pdcd4 has been convincingly demonstrated to suppress neoplastic transformation, tumorigenesis, and invasion (Yang et al., 2006) , it has not been investigated so far whether other steps in tumor progression, especially intravasation and metastasis, can be regulated by Pdcd4. Moreover, little is known of the functionally significant Pdcd4 target genes.
The urokinase receptor (u-PAR) is a 55-60 kDa heavily glycosylated, disulfide-linked cell surface receptor which, by its ligand u-PA, leads to a very efficient plasmin-mediated degradation of extracellular matrix components such as fibrin and collagen IV (Ossowski et al., 1991; Blasi, 1993) . Thus it is one of the molecules promoting invasion and metastasis that has repeatedly been shown to be predictive of a poor clinical prognosis of diverse carcinomas (Janicke et al., 1993; Ganesh et al., 1994; Nekarda et al., 1994; Heiss et al., 1995) . In cancer, a high expression of u-PAR is mainly brought about at the transcriptional level, although other mechanisms at the post-transcriptional level may be involved (Wang et al., 1994; Shetty et al., 1997) . In our recent work, we had shown that a motif spanning region À152/À135 of the u-PAR promoter bound by an AP-2-like transcription factor, Sp3 and Sp1, was required for a high u-PAR gene expression in cultured colon cancer cells, the AP-2-like protein mediating a high constitutive and PMA-inducible expression, Sp1, a high u-PAR gene expression caused by the c-src-oncogene (Gallick and Jessup, 1992; Allgayer et al., 1999a, c) . Another AP-1 consensus motif (À190/À171) regulates constitutive and phorbol ester-induced u-PAR gene expression in colon cancer, as well as u-PAR gene expression brought about by mutation-activated K-ras (Lengyel et al., 1996; Allgayer et al., 1999b) . A PEA3/etssilencer-motif further upstream (at À248 bp) mediates a downregulation of u-PAR gene expression by b 3 -integrin. Further promoter regions containing putative transcription factor binding sites, e.g. À99/À70 (Sp-1 motifs driving basal expression), or À402/À350 (putative Sp-1, GATA-2 and NF-1 motifs) have been described (Hapke et al., 2001) . Thus, expression of the invasion-related gene u-PAR is transcriptionally regulated by diverse promoter elements. So far, no tumor suppressor has been described, which acts on invasion, migration or metastasis by suppressing u-PAR gene expression.
In consequence, the present study was undertaken (1) to confirm Pdcd4 suppression of invasion and to investigate whether tumor suppressor Pdcd4 can suppress tumor cell intravasation, (2) to determine whether this might be achieved, at least in part, by regulating u-PAR, and (3) to indicate transcription factors and cis-elements by which this regulation is mediated. Our results extend the observation that Pdcd4 suppresses invasion, moreover suppressing tumor cell intravasation. Pdcd4 regulates u-PAR expression in cultured colon cancer cells, at least in part, by regulating Sp1/Sp3 transcription factors. This is the first study to suggest Sp3/Sp1 as downstream mediators of Pdcd4.
Results
Pdcd4 inversely regulates u-PAR gene expression in cancer cell lines, and correlates inversely with u-PAR protein/mRNA in resected colorectal cancer We first determined expression of u-PAR and Pdcd4 in 14 different cancer cell lines (colorectal, gastric, breast, lung cancer) by enzyme-linked immunosorbent assay (ELISA), quantitative reverse transcription with polymerase chain reaction (RT-PCR) and Western blotting (Figure 1a) . In cell lines with high endogenous amounts of u-PAR (e.g. RKO, lane 1, Figure 1a , upper panel), a low amount of endogenous Pdcd4 protein at 64 kDa was observed (e.g. RKO, lane 1 Figure 1a , lower panel), whereas cell lines with low u-PAR amounts (e.g. GEO, lane 2, Figure 1a , upper panel) showed high amounts of Pdcd4 (e.g. GEO, lane 2, Figure 1a , lower panel). Correspondingly, in RT-PCR analysis ( Figure 1a , middle panel), reciprocal amounts of steady-state mRNA for u-PAR, as compared to Pdcd4 protein were seen in these cell lines. A significant inverse correlation between Pdcd4 protein and u-PAR protein or u-PAR mRNA was observed (P ¼ 0.007, P ¼ 0.008, w 2 ) in these 14 cell lines. To corroborate a reciprocal expression of endogenous human Pdcd4 and u-PAR in vivo, resected tumor and corresponding normal tissues of 29 patients with colorectal cancer were analysed for Pdcd4 protein (Western) and u-PAR protein (ELISA)/u-PAR mRNA quantitative RT-PCR (qRT-PCR). Representative examples are shown in Figure 1b . Within these 29 patients, we observed a significant negative correlation between Pdcd4 protein, and u-PAR protein (P ¼ 0.019) and u-PAR mRNA (P ¼ 0.016).
Next, GEO colon cancer cells being characterized by a high endogenous expression of Pdcd4 were made to suppress natural Pdcd4 protein by transfection of a Pdcd4-siRNA (Figure 2a ). Pdcd4 knockdown GEO cells showed a clear increase in endogenous u-PAR mRNA (Figure 2b) , and u-PAR protein as shown by ELISA (Figure 2c ). Taken together, these data suggest that Pdcd4 is a suppressor of u-PAR gene expression in cultured colon cancer and further cell lines, and that this can be supported by in vivo data from patients with resected colorectal cancer.
Pdcd4 regulates the u-PAR gene promoter in colon cancer cells Next, we sought to investigate molecular mechanisms mediating Pdcd4-induced u-PAR gene regulation. We previously reported that u-PAR gene expression in cultured colon cancer is largely due to a transcriptional activation of the gene, and diverse cis-elements of the u-PAR promoter were characterized as being essential for this regulation (Wang et al., 1994; Lengyel et al., 1996; Allgayer et al., 1999c) . We, therefore, asked as to whether Pdcd4 is able to regulate u-PAR gene expression at the promoter level. In GEO cells being characterized by high endogenous Pdcd4 and low endogenous u-PAR (Allgayer et al., 1999b; Allgayer et al., 1999c) a siRNA specifically downregulating endogenous Pdcd4 led to a significant increase of activity of a luciferase reporter driven by À398 bp upstream of the main transcriptional initiation site of the u-PAR gene (Figure 3a) . The À398 bp corresponds to the basal u-PAR promoter as described previously (Lengyel et al., 1996; Allgayer et al., 1999c) . In RKO cells, being characterized by a high endogenous u-PAR promoter activity and u-PAR gene expression (Allgayer et al., 1999a, c) , transient transfections with a CAT reporter driven by the À398 bp u-PAR promoter, and increasing amounts of a pdcd4 expression construct, were performed. As compared to empty-vector control transfections, a clear and dose-dependent reduction of u-PAR promoter activity was seen with pdcd4 expression (Figure 3b ). To corroborate these results with an extended promoter construct including additional upstream regulatory motifs, the experiment was repeated using a luciferase reporter driven by À1498 bp upstream of the main transcriptional start site of the u-PAR gene. This construct contains additional putative enhancer/ silencer motifs (Hapke et al., 2001) . As can be seen, an inhibition of activity could also be observed for the Figure 1 Reciprocal expression of Pdcd4 and u-PAR in 14 cancer cell lines, and inverse correlation of Pdcd4 with u-PAR protein/ mRNA in resected colorectal cancer. Protein extracts from different cancer cells (a) or from 29 tumor and corresponding normal tissues -five representative examples shown -(b) were prepared and subjected to Western blotting with polyclonal anti-Pdcd4 antibody. Equal amounts of protein were confirmed using an monoclonal anti b-actin antibody (AC-15). The same lysates were subjected to an ELISA to determine u-PAR protein amounts. In parallel, total RNA was extracted, reverse-transcribed and quantified by real-time PCR using specific TaqMan primers and probes for human u-PAR. Samples were analysed in quadruplicates, and relative u-PAR expression levels normalized against b-actin. u-PAR amounts are shown as a relative quantification, with corresponding expression level of wild-type RKO cells as a reference. A significant negative correlation between Pdcd4 protein, and u-PAR mRNA or u-PAR protein was observed for cell lines (P ¼ 0.008, P ¼ 0.007, w 2 ) and for 29 tumor and normal tissues (P ¼ 0.016, P ¼ 0.019, w 2 ).
u-PAR promoter extended by additional upstream motifs ( Figure 3c ). Taken together, these data suggest that expression of pdcd4 results in a suppression of transcription from the u-PAR promoter.
Delineation of putative cis-elements of the u-PAR promoter mediating Pdcd4-regulated u-PAR gene expression: Sp1/Sp3 but not AP-1 sites appear important Next, we sought to delineate putative cis-elements within the u-PAR promoter mediating Pdcd4-induced suppression. As a first step to narrow down putative sequences within the extended u-PAR promoter (À1498), luciferase constructs driven by diverse deletions of defined promoter regions (Hapke et al., 2001 ) were compared to the wild-type À1498 promoter for Pdcd4-induced promoter suppression, in transient transfections of RKO cells. As can be seen (Figure 4a ), the inhibitory effect of pdcd4 expression on the extended u-PAR promoter was abolished with a promoter construct deleted for region À402/À350 which contains putative Sp1, NF-1 and GATA-2 sequences (Hapke et al., 2001) . Next, we asked as to whether an AP-1 consensus motif (À190/À171, (Lengyel et al., 1996) ), and a combined motif that bound an AP-2-like protein, Sp1 and Sp3 (Allgayer et al., 1999c) within the À398 bp basal u-PAR promoter, which we had characterized extensively in previous works, might participate in Pdcd4-mediated u-PAR promoter regulation. Transient transfections and CAT-assays of RKO cells with CAT-reporter-constructs driven by mutations abolishing the binding of AP-1 transcription factors to region À190/À171, Sp1/Sp3 to region À152/ À135, and AP-2/Sp1 and Sp3 to region À152/À135, respectively, were conducted in parallel to transfections with a wild-type-(À398)-u-PAR promoter-CAT reporter, and compared for their ability to abolish Pdcd4-induced promoter suppression ( Figure 4b ). Whereas the AP-1-mutated (À190/À171) promoter construct could still be inhibited by pdcd4 expression (Figure 4b , lanes 3 and 7), the u-PAR promoter construct mutated for Sp1/Sp3 binding to region À152/À135 lost sensitivity to Pdcd4 expression, that is, showed equal activity with and without pdcd4 co-transfection ( Figure 4b , lanes 4 and 8).
The same was observed for a promoter construct mutated for the binding of the AP-2-like transcription factor, described in a previous work (Allgayer et al., 1999c) , and Sp1/Sp3 simultaneously ( Figure 4b , lanes 5 and 9). In addition, a u-PAR promoter construct deleted for region À148/À124 unable to bind the AP-2-like protein, Sp1 and Sp3 was not inhibited by pdcd4 expression in contrast to the wild-type u-PAR promoter ( Figure 4c , lanes 4 and 5). These data suggest that u-PAR promoter region À152/À135, in addition to the upstream region À402/À380 shown above, is a co-mediator of Pdcd4-induced u-PAR promoter suppression, and that abolishing the binding of Sp1/Sp3 transcription factors to this region is sufficient to abrogate Pdcd4-mediated u-PAR promoter suppression, indicating Sp1/Sp3 bound to this region as crucial mediators of this suppression.
Sp3 and Sp1 as potential downstream mediators of Pdcd4-regulated u-PAR gene expression
To corroborate the results from reporter analysis which suggested region À152/À135 as one of the cis-elements mediating Pdcd4-regulated u-PAR promoter activity, and to define whether the binding of Sp1/Sp3, the AP-2-like protein transcription factor or a combination of these factors, to region À152/À135 of the u-PAR promoter would be important for this regulation, electrophoretic mobility shift assay (EMSA) analyses for u-PAR promoter region À152/À135 were performed using a 33 P-end-labeled oligonucleotide corresponding to Pdcd4 regulates invasion and u-PAR expression JH Leupold et al this region and equal amounts of standardized nuclear extract of RKO colon cancer cells made to overexpress pdcd4, respectively. In previous publications, we had shown that binding of an AP-2-like transcription factor, Sp1 and also Sp3, to region À152/À135 of the u-PAR promoter is seen at this region using these cell lines, represented by three specific bands of slower mobility (Allgayer et al., 1999c) . The upper of these bands represents Sp1 binding, the intermediate Sp3 binding and the lowest band is of the AP-2-like transcription factor as demonstrated previously (Allgayer et al., 1999c) . Binding of these three transcription factors in pdcd4-expressing RKO clones can be seen in Figure 5a . Whereas there is no difference in binding intensity of the AP-2-like transcription factor to promoter region À152/À135 between pdcd4-and mock-transfected cells, there is a clear increase in Sp3 binding to this promoter region in the cells expressing pdcd4 (Figure 5a, lane 3) . This was confirmed in a chromatin immunoprecipitation (ChIP) analysis for the same region, in which a clear increase of Sp3-binding in Pdcd4-transfected RKO cells to the natural u-PAR promoter motif was observed (Figure 5d, middle panel, lanes 4 and 8) . In addition, in ChIP a decrease of Sp1 binding to this motif was seen after Pdcd4 transfection (Figure 5d , middle panel, lanes 3 and 7). This supports the notion that Sp3 binding to promoter region À152/À135 is induced by Pdcd4, and that Sp3 acts as trans-suppressor of u-PAR promoter activity in this scenario. Sp1, in contrast, as a transactivator at this region, is being suppressed by Pdcd4.
Since our results regarding promoter region À152/ À135 indicated an important role of Sp family transcription factors in Pdcd4-mediated u-PAR gene expression, we performed additional EMSA analyses for region À402/À350, which contains a putative Sp-1, GATA-2 and NF-1 motifs (Hapke et al., 2001 ) and which was indicated as an additional mediator in previous reporter experiments (see Figure 4a ). EMSA analysis for the GATA-2 and NF-1 motif within this region did not show any differences in transcription factor binding between pdcd4-and mock-transfected cells (data not shown). However, when an oligonucleotide corresponding to the Sp motif (À380/À354) of region À402/À350 was incubated with nuclear extract of pdcd4-expressing and mock-transfected RKO cells, a decrease in Sp binding was observed in Pdcd4-expressing cells (Figure 5b ). This binding was specifically inhibited by adding increasing amounts of an unlabeled consensus oligonucleotide specific for Sp transcription factors (Figure 5c ). Finally, ChIP for this region in GEO cells transfected with siRNA-Pdcd4 showed an upregulation of Sp1 binding to the natural promoter region (Figure 5d, lower panel, lanes 3 and 7) , in addition to an increase in Sp3 binding to this motif in this cell line (lanes 4 and 8) . Therefore, interestingly, Sp3 at this motif, in contrast to the downstream motif (À152/ À135), might function as a transactivator in addition to Sp1, both getting upregulated by knockdown of Pdcd4. Taken together, our data suggest that Sp1 and Sp3 binding to promoter elements À152/À135 and À380/À354 are important mediators of Pdcd4-induced suppression of u-PAR promoter activity and that Pdcd4 appears to inhibit Sp binding at two important motifs on the u-PAR promoter.
Pdcd4 inhibits tumor cell invasion and intravasation
Finally, as Pdcd4 was capable of suppressing expression of the invasion-related gene u-PAR, at least in part via transcriptional mechanisms, we sought to determine as to whether different steps of invasion can be inhibited by Pdcd4. This objective was addressed using two different models. First, pdcd4-transfected RKO cells were subjected to a Matrigel invasion assay as compared to mock-transfected RKO cells (Figure 6a ). In three independent experiments, Pdcd4-expressing cells showed significantly less invasion into Matrigel than mocktransfected RKO cells (Figure 6a) . Second, an in vivo intravasation assay measuring invasion into the upper chorionallantoic membrane, and intravasation into blood vessels of chicken embryos, was applied (Ossowski, 1988) . Pdcd4-overexpressing RKO cells were incubated on the upper chorionallantoic membrane of 9-day-old chicken embryos as compared to mock-transfected cells, allowed to invade the upper chorionallantoic membrane, and subsequently intravasate into embryonic vessels, the number of intravasated cells being measured by human Alu-PCR from the lower chorionallantoic membrane as described previously (Kim et al., 1998) . Significantly less intravasation in vivo represented by human Alu-PCR of the lower chorionallantoic membrane was observed for pdcd4-expressing, u-PAR-suppressed RKO cells (Figure 6b ). These data suggest Pdcd4 not only suppresses invasion as shown previously, but also intravasation.
Discussion
This is the first study describing a role of the transformation and invasion suppressor Pdcd4 in the regulation of the invasion-related gene u-PAR, and of intravasation. It is, furthermore, the first study to suggest Sp3/Sp1 as downstream mediators of Pdcd4.
Pdcd4 has been identified as a suppressor of malignant transformation (Cmarik et al., 1999; Yang et al., 2001a Yang et al., , b, 2003a , tumorigenesis and tumor Figure 3 u-PAR promoter activity is downregulated by Pdcd4 overexpression and upregulated by knockdown of Pdcd4. (a) GEO cells were transfected with 0.08 mg of a luciferase-reporter plasmid driven by À398 bp of the wild-type u-PAR promoter (pGl3u-PAR-398), 0.02 mg of a renilla vector as an internal control, together with an siRNA specific for Pdcd4 or an unspecific (scrambled) siRNA at a final concentration of 40 nM. Cells were cultured for 72 h and assayed for luciferase activity. (b) RKO cells were transiently transfected with 0.8 mg of a CAT-reporter plasmid driven by À398 bp of wild-type u-PAR promoter (u-PARCAT), 0.8 mg of pSV0CAT as a negative control and the indicated amounts of either the empty vector (pcDNA3.1(À)) or the Pdcd4 expression vector (pcDNA3.1(À)Pdcd4). After 48 h, the cells were harvested, lysed and assayed for CAT activity. The amount of acetylated [ 14 C]chloramphenicol was determined with a phosphoimager (BAS 1500, Fuji, Raytest, Germany) using AIDA software. All CAT reporter transfections were performed in the presence of a luciferase expression vector (0.2 mg), and transfection efficiencies were determined by assaying for luciferase activity. The data are representative of three different experiments, the range of which did not exceed 10%. (c) RKO cells were transfected with 0.8 mg of a luciferase reporter plasmid regulated by À1469 bp of the wild-type u-PAR promoter (u-PAR-1469), 0.2 mg of a renilla luciferase vector as internal control together with indicated amounts of pcDNA3.1(À) or pcDNA3.1(À)Pdcd4. After 48 h, cells were lysed and assayed for luciferase activity. Samples were analysed in octaduplicates and normalized against renilla luciferase activity. Data are the mean7s.d. from at least three independent experiments. Differences between the activity of the luciferase construct with and without Pdcd4 expression were significant (Po0.05), indicated with (n).
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progression (Jansen et al., 2005) , invasion and matrix metalloproteinase activation (Yang et al., 2006) and tumor growth (Stalberg et al., 2001) . It is also identified as a correlate of induced apoptosis (Shibahara et al., 1995; Zhang and DuBois, 2001 ) and cellular senescence (Kang et al., 2002) . In the present work, we now suggest Pdcd4 to suppress the invasion cascade of cultured colon cancer with two different models. Specifically, Figure 4 Pdcd4 regulates u-PAR promoter through Sp1/Sp3, but not AP-1 or AP-2 elements. (a) RKO cells were transfected with 0.08 mg u-PAR-1469 or the indicated deletion construct, including an Sp-binding motif (u-PAR-1469Del1), 0.02 mg renilla luciferase vector as an internal control, together with either 0.1 mg of the the empty vector (pcDNA3.1(À)) or the Pdcd4 expression vector (pcDNA3.1(À)Pdcd4). The cells were cultured 48 h, lysed and assayed for luciferase activity. Samples were analysed in octaduplicates and normalized against renilla luciferase activity. (b) and (c) RKO cells were transiently transfected with 0.8 mg u-PARCAT together with 3 mg of pcDNA3.1(À)) or pcDNA3.1(À)Pdcd4. As a negative control 0.8 mg of pSV0CAT was used. After 48 h, the cells were harvested, lysed, and assayed for CAT activity. The amount of acetylated [ 14 C]chloramphenicol was determined with a phosphoimager (BAS 1500, Fuji, Raytest, Germany) using AIDA software. The data are representative of three different experiments, the range of which did not exceed 10%.
over and above the Matrigel assay, the chicken embryo metastasis (CAM) model is an in vivo assay able to measure intravasation of tumor cells into blood vessels following invasion of the upper chorionallantoic membrane (Ossowski 1988; Kim et al., 1998) . Therefore our data suggest that Pdcd4 can inhibit at least two different steps in the metastatic cascade, which are local invasion into surrounding matrix (as shown by Matrigel), and intravasation (as shown by the CAM model). Our data are supported by the negative correlation of Pdcd4 and u-PAR in a series of resected patient samples as presented here, and by further clinical data by Chen et al. (2003) , who demonstrated that Pdcd4 is downregulated in malignant lung tumors as compared to normal tissues, which is significantly associated with tumor dedifferentiation (G3) and advanced tumor stage. Final PCR was carried out using 1 ml of DNA. The upper panel shows a schematic presentation of the region of the u-PAR promoter used for amplification. Primersets used for PCR after the chromatin immunoprecipitation are indicated as primer set I and primer set II. PCR products were separated in an 1.5% agarose gel and visualized by ethidiumbromide staining. The middle panel shows a ChIP-analysis for Pdcd4-transfected RKO cells for the endogenous u-PAR promoter motif À152/À135, confirming an upregulation of Sp3, and additionally showing downregulation of Sp1 at this motif by Pdcd4. The lower panel shows a ChIP analysis for region À380/À354 in GEO cells transfected with siPdcd4. An upregulation of Sp1 binding to the natural promoter region, and also of Sp3, is observed in siPdcd4-transfected GEO cells.
Although this study has been performed at a rather small series of patient tissues (n ¼ 47), these results support the notion that loss of Pdcd4 is associated with disease progression and biologically invasive tumors. The phenomenon that a loss of Pdcd4 expression is required for cancer progression has been further supported by recent findings in one of our laboratories (Schmid et al., submitted) and further explains the observations made by us and our colleagues that it is not possible to maintain long-term Pdcd4-stably transfected cultured cancer cells.
Our present work suggests that the suppression of migration and invasion by Pdcd4 is, at least in part, brought about by a downregulation of the urokinase receptor (u-PAR), which, together with its binding enzyme u-PA and its specific inhibitor PAI-1, has been well established as a proteolytic system promoting invasion/metastasis and a poor clinical prognosis in diverse cancers (Duffy, 1987; Blasi, 1993; Heiss et al., 1996; Muehlenweg et al., 2001) . Although it is well established that u-PAR is regulated by many growth factors, oncogenes (Boyd and Brattain, 1989; Lengyel et al., 1996; Allgayer et al., 1999a-c) and signaling cascades promoting proliferation/progression (AguirreGhiso et al., 2001; Aguirre-Ghiso et al., 2003; Ahmed et al., 2003) , no tumor suppressor gene has been identified so far regulating u-PAR gene expression (Fuchs and Allgayer, 2003) . According to previous studies, the regulation of u-PAR gene expression has largely been observed at the transcriptional level (Wang et al., 1994; Wagner et al., 1995; Lengyel et al., 1996) , and correspondingly, we showed that Pdcd4 reduces u-PAR promoter activity, and that siPdcd4 induces u-PAR mRNA, in our cell lines studied, suggesting transcriptional regulation. Moreover, the significant inverse correlation between Pdcd4 protein and u-PAR mRNA in 29 resected patient tumors supports this notion. However, there have been reports suggesting 5 RKO cells were inoculated on the upper chorioallantoic membranes of chicken embryos, the DNAs of the lower chorioallantoic membranes were extracted, and the genomic DNAs were used to amplify human Alu sequences in the presence of 33 P-dCTP, and analysed by PAGE and autoradiography. The intensity of the 220 bp band (human Alu) increased with increased content of human cancer cells in the lower chorioallantoic membranes. Bands were scanned densitometrically and shown as a bar diagram. Differences between mock-transfected RKO cells with Pdcd4-expressing RKO cells were statistically significant (Po0.008), indicated with (n).
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JH Leupold et al post-transcriptional modifications such as mRNA stability as additional mechanisms (Shetty et al., 2004) . Since Pdcd4 has been demonstrated to selectively suppress translation (Yang et al., 2003a; Zakowicz et al., 2005) , we speculate that Sp1 might be a translational target of Pdcd4 that in turn regulates u-PAR transcription.
Our reporter assays using deletions and mutations of the u-PAR promoter indicated an upstream Sp-binding motif within region À402/À380, and especially our previously characterized combined AP-2/Sp1/Sp3 motif at À152/À135, as potential mediators of Pdcd4-induced u-PAR gene suppression. This was surprising as previous data so far have suggested a role of AP-1-transcription factors, but not NF-kB or SRE as transcriptional mediators of Pdcd4-induced gene regulation (Yang et al., 2001a (Yang et al., , b, 2003a . AP-1-regions and an NF-kB motif have been identified in the u-PAR promoter being involved in diverse means of u-PAR regulation (Lengyel et al., 1996; Wang et al., 2000) . Our finding that Pdcd4 regulates u-PAR via Sp1/Sp3 motifs, rather than via AP-1, poses a further example for the well-known notion that regulators may use different mediators to regulate different sets of genes. Our data add to our finding that the combined AP-2/Sp1/Sp3 u-PAR promoter element characterized previously (Allgayer et al., 1999c) is indeed an important differential regulator of u-PAR gene expression, mediating constitutive, PMA-inducible, Src-inducible, and now also Pdc4-induced regulation, the latter being specifically mediated by an increase in Sp3 binding to this motif. From our previous data in GEO colon cancer cells, where we observed a decrease in Sp3 binding to this promoter region À152/À135 upon stimulation with PMA (Allgayer et al., 1999c) , we already had speculated that Sp3 might be a trans-repressor at this motif. This notion is now supported by present data since Sp3 binding to this motif was increased following transfection with a tumor suppressor, Pdcd4. In contrast, a decrease in Sp1 binding to this region (ChIP) and to u-PAR promoter region À402/À380 brought about by Pdcd4 was observed in our study, allowing the hypothesis that, in this case, Sp1 is a transactivator at this particular u-PAR promoter motif, binding of which is being suppressed by Pdcd4. Our finding that Sp1 and Sp3 have opposing roles at two different motifs of the u-PAR promoter is supported by other reports which have shown that Sp-group transcription factors can act both as enhancers or inhibitors of transactivation (Qin et al., 1999; Ritchie et al., 2000) .
The mechanisms by which Pdcd4 might lead to an increase or reduction of Sp1/Sp3 binding to promoter regions merit discussion. It has been well established that the DNA binding and transactivating activity of Sp transcription factors are largely modulated by posttranslational modifications such as phosphorylation (Su et al., 1999; Yang et al., 2001a, b) . Also, an earlier study reported that Pdcd4 blocks phosphorylation of c-Jun, this being achieved either via JNK regulation or direct interaction with c-Jun (Bitomsky et al., 2004) . More recently, we have shown that pdcd4 inhibits c-Jun N-terminal phosphorylation by targeting expression of Map4K1 with consequent inhibition of signaling to activate Jun kinase and AP-1 needed for invasion (Yang et al., 2006) . Thus it is conceivable that Pdcd4 might also interfere with phosphorylation of Sp transcription factors by inhibiting translation of activating/repressing kinases, thereby regulating DNA affinity. However, different reports on Pdcd4 suggest that it inhibits translation by physical interaction with translation initiation factor eIF4A and eIF4G, among other effects involving translation. Concerning Pdcd4-linked transrepression of AP-1, it has been shown that binding of Pdcd4 to eIF4A and inhibition of translation are required for transrepression of AP-1 (Yang et al., 2003a, b; Zakowicz et al., 2005) . Thus, one might speculate that in the regulation of Sp transcription factors, similar mechanisms modulating translation might be involved and that Sp1 might be expected to be a direct target of translational regulation by Pdcd4 while Sp3 might be an indirect target. Further investigations need to elucidate either of these possibilities in Pdcd4-induced Sp regulation.
Taken together, the present paper suggests that Pdcd4, besides its function as a suppressor of transformation, tumorigenesis and invasion, has an additional role in suppressing tumor intravasation. Pdcd4's inhibition of invasion and intravasation appears to be brought about, at least in part, by regulating the Sp1/Sp3-mediated u-PAR gene expression. These observations add further support to the expectation that elevating or mimicking Pdcd4 expression offers promising possibilities for inhibiting tumor progression and metastasis in cancer patients.
Materials and methods
Materials, patient tissues, antibodies, cell lines and plasmids Media/FBS were purchased from Invitrogen/Gibco (Karlsruhe, Germany) and Sigma (Taufkirchen, Germany). The following antibodies were from Santa Cruz (Santa Cruz, CA, USA): Sp1 (sc-59X), Sp3 (sc-644X), unspecific IgG. b-Actin antibody (mouse monoclonal antibody (mAB) AC-15) was from Sigma. The affinity-purified antibody against a Cterminal peptide of Pdcd4 (Jansen et al., 2004) and the Pdcd4 expression plasmid (Yang et al., 2001a) were used as described. Reporter plasmids for u-PAR were gifts from D Boyd (Cancer Biology, MD Anderson Cancer Center, Houston, MA, USA), and E Lengyel (Gynecology, University of Chicago, IL, USA (Hapke et al., 2001) ). Oligonucleotides were supplied by Metabion (Martinsried, Germany). An Sp-consensus-oligonucleotide (Santa Cruz) was applied for gelshift competition. Transwell chambers (1 cm 2 , 12 mm pore size) were from Costar (Cambridge, MA, USA), thin-layer chromatography plates (SIL G-25 UV254) from Machery-Nagel (Du¨ren, Germany). Matrigelt was purchased from BD Biosciences (Bedford, MA, USA). GEO cells were a gift from D Boyd (Boyd et al., 1988) . All other cell lines were obtained from ATCC (Rockville, MD, USA). Fertilized SPF-eggs (special pathogen free) were obtained from Charles River (Hilden, Germany). Tissue specimens (tumor, normal mucosa) of 29 patients with colorectal cancer were collected after informed consent and verification by a pathologist, and immediately frozen in liquid nitrogen.
Invasion assay
The Matrigel assay was performed as described previously with some modifications (Albini et al., 1987) . Briefly, 5 Â 10 5 cells were plated on transwell chambers precoated with 10 mg Matrigel. Medium containing 20ngEGF (Sigma) served as chemoattractant. Following 16 h of incubation, non-invading cells were removed with cotton swabs. Invading cells were stained with crystal violet or trypsinized and counted using the ATP-luminescence-based motility-invasion assay as described previously (Monte et al., 2002) .
Chicken embryo metastasis (CAM) assay
The CAM assay was performed as previously described using 0.3 Â 10 6. cells for each egg (Kim et al., 1998; Zijlstra et al., 2002) . Genomic DNA from chicken chorioallantoic membranes was prepared using the Puregene DNA purification system according to the manufacturer's instructions (Gentra Systems, Minneapolis, MA, USA) and used for amplification of human ALU sequences by PCR.
Reporter assays, RNA interference and transfection Cells were transfected using Lipofectamine2000 (Invitrogen) according to manufacturer's protocol. CAT assays were performed as described previously (Lengyel et al., 1996) , and luciferase assays according to the manufacturer's protocol (Promega, Madison, WI, USA). GEO cells were transfected with siRNAs that specifically target the Pdcd4 gene or a nonsilencing control (#4611G, Ambion, Austin, TX, USA). Sequence of Pdcd4-specific siRNA: 5 0 -GGUGGCUGGAA CAUCUAUUtt-3 0 . As it is generally experienced with the transfection of a tumor suppressor gene, attempts to establish/ maintain long-term stable clones with exogenously induced Pdcd4 repeatedly failed in diverse cell lines with low endogenous Pdcd4, including RKO. Therefore, experiments were done with Pdcd4-transfected clones which could be held in culture for days or weeks. New transfections were established repeatedly after older clones died. Short-term experiments such as luciferase assays were performed at least in triplicate, after separate and independent transient transfections with at least 85% transfection efficiency.
Nuclear extracts, EMSA and ChIP Preparation of nuclear extracts and EMSAs were done as described by Schewe et al. (2005) , using oligonucleotides spanning regions À152/À135 (5 0 -CCAGCCGGCCGCGCC CCGGGAAGGGA-3 0 ) and À380/À354 (5 0 -ATACCAG TATCCCTCCTGACAAAACTA-3 0 ) of the u-PAR promoter. ChIP assays were performed using anti-Sp1, anti-Sp3 and IgG according to the manufacturer's instructions (Upstate, Charlottesville, VA, USA). Immunoprecipitated DNA was purified using QIAquick Spin Kit (Qiagen Hilden, Germany) and subjected to PCR-amplification using specific primersets (primerset I: Forward, 5 0 -GGAAGCAAAGCAAGGGTTAA G-3 0 ; Reverse, 5 0 -TCGCTCTCCACTGCTGTAAA-3 0 for region À380/À354, primerset II Fwd 5 0 -AGGCAATCTGGG GACAGAG-3 0 ; Rev 5 0 -GGACTCCTCCCAGACGTTTT-3 0 for region À152/À135).
Total RNA extraction, cDNA synthesis and real-time PCR Total RNA from cell lines was extracted using the RNeasy Mini Kit (Qiagen), and total RNA from tissue specimens using TRIzol Reagent (Invitrogen). For real-time PCR, 500ng of total RNA was reverse-transcribed in a total volume of 25 ml using oligodT. The cDNA was diluted 1:50, and 5 ml was used for quantification using ABI PRISM 7000 (Applied Biosystems, Foster City, CA, USA), with the TaqMan Gene Expression Assay for u-PAR (Hs00182181_m1) or Pdcd4 (Hs00377253_m1). Human b-actin (human ACTB) TaqMan assay served as an internal control.
Western blotting, immunoprecipitation and ELISA Cell or tissue lysis, quantification of lysate protein and Western immunoblotting were performed as described (Dikic et al., 1995) . u-PAR in resected tissues was assayed using the Imubind-u-PAR-ELISA kit (American Diagnostica, Greenwich, CT, USA) according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed using StatView5.0. for Macintosh/Windows. For correlation analysis between Pdcd4/u-PAR in cell lines and resected patient tissues, values were dichotomized at the median, and analysed by w 2 -analysis. For reporter and invasion/intravasasion experiments, differences between groups were calculated with the Wilcoxon test for independent values. A P-value of o0.05 was defined as significant, ofo0.1 as a trend.
